Clinical Trials Browser

Phase 1 × nazartinib × Thoracic × Clear all

EGFR-mutant Non-small Cell Lung Cancer

NCT03516214 2024-02-15

EATON

Phase 1 Completed

18 enrolled

Thoracic

Bronchial Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

283 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Clinical Trials

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EATON

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)